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Statistical Methods for Evaluating and
Comparing Biomarkers for Patient Treatment
Selection
Holly Janes, Marshall D. Brown, Margaret S. Pepe, Ying Huang

Abstract
Despite the heightened interest in developing biomarkers predicting treatment response that are used to optimize patient treatment decisions, there has been relatively little development of statistical methodology to evaluate these markers.
There is currently no unified statistical framework for marker evaluation. This
paper proposes a suite of descriptive and inferential methods designed to evaluate
individual markers and to compare candidate markers. An R software package has
been developed which implements these methods. Their utility is illustrated in the
breast cancer treatment context, where candidate markers are evaluated for their
ability to identify a subset of women who do not benefit from adjuvant chemotherapy and can therefore avoid its toxicity.
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1 Introduction
There is an enormous amount of research effort being devoted to discovering and
evaluating markers that can predict a patient’s chance of responding to treatment.
A November, 2012 PubMed search identified 7,602 papers evaluating such markers
from 2011 and 2012 alone. Treatment selection markers, sometimes called “predictive” (Simon (2008)) or “prescriptive” (Gunter, Zhu, and Murphy (2007)) markers,
have the potential to improve patient outcomes and reduce medical costs by allowing treatment provision to be restricted to those patients most likely to benefit, and
avoiding treatment in those only likely to suffer its side effects and other costs.
Methods for evaluating treatment selection markers are much less well developed than for markers used to diagnose disease or predict risk under a single
treatment. In the medical literature, the most common approach to marker evaluation is to test for a statistical interaction between the marker and treatment in
the context of a randomized and controlled trial (see Coates, Miller, O’Toole, Molloy, Viale, Goldhirsch, Regan, Gelber, Sun, Castiglione-Gertsch, Gusterson, Musgrove, and Sutherland (2012), Busch, Ryden, Stal, Jirstrom, and Landberg (2012),
Malmstrom, Gronberg, Marosi, Stupp, Frappaz, Schultz, Abacioglu, Tavelin, Lhermitte, Hegi, Rosell, Henriksson, and (NCBTSG) (2012) for some recent examples).
However this approach has limitations in that it does not provide a clinically relevant measure of the benefit of using the marker to select treatment and does not
facilitate comparing candidate markers (Janes, Pepe, Bossuyt, and Barlow (2011)).
Moreover, the scale and magnitude of the interaction coefficient will depend on the
form of the regression model used to test for interaction, and on the other covariates
included in this model (Huang, Gilbert, and Janes (2012)).
There is a growing literature on methods for evaluating treatment selection
markers. A number of papers have focused on modeling the treatment effect as a
function of marker (see Bonetti and Gelberr (2004), Royston and Sauerbrei (2004),
Claggett, Zhao, Tian, Castagno, and Wei (2011), Zhao, Tian, Cai, Claggett, and
Wei (2011)), some have proposed individual measures for evaluating markers (see
Song and Pepe (2004), Vickers, Kattan, and Sargent (2007), Brinkley, Tsiatis, and
Anstrom (2010), Janes et al. (2011), Huang et al. (2012)), and others have focused
on the specific problem of optimizing marker combinations for treatment selection
(Lu, Zhang, and Zeng (2011), Foster, Taylor, and Ruberg (2011), Zhang, Tsiatis,
Laber, and Davidian (2012), McKeague and Qian (2011)). A complete framework
for marker evaluation, on par with those developed for evaluating classification
markers (Pepe (2003), Zhou, McClish, and Obuchowski (2002)) or risk prediction
markers (Pepe and Janes (2012)), is still forthcoming.
In this paper, we lay out a comprehensive approach to evaluating markers
for treatment selection. We propose tools for descriptive analysis and summary
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measures for formal evaluation and comparison of markers. The measures are, in
many cases, extensions of those used to evaluate markers for predicting outcome
under a single treatment, i.e. for risk prediction. Our global measure of preference
is the same as or closely related to that advocated in recent methodological work on
treatment selection markers (Song and Pepe (2004), Vickers et al. (2007), Brinkley
et al. (2010), Janes et al. (2011), Claggett et al. (2011), Huang et al. (2012), Zhang
et al. (2012), McKeague and Qian (2011)). We develop methods for estimation
and inference that apply to data from a randomized controlled trial comparing two
treatment options where the marker is measured at baseline on all or a stratified
case-control sample of trial participants. For illustration, we consider the context
of breast cancer treatment where candidate markers are evaluated for their utility
in identifying a subset of women who do not benefit from adjuvant chemotherapy.
Appendices include the results of a small-scale simulation study that evaluates the
performance of the methods in finite samples and a description of the R package we
have written that implements these methods.

2 Setting and Notation
Suppose that the task is to decide between two treatment options, referred to as
“treatment” (T = 1) and “no treatment” (T = 0). The clinical outcome of interest, D,
is a binary indicator of an adverse event within a specific time-frame following treatment provision; we refer to this outcome as “disease”. The outcome D is thought
to capture all potential impacts of treatment, so that any decrease in the rate of disease justifies treatment. To achieve this, D may be chosen to represent a composite
outcome such as an indicator of treatment-associated toxicity or death. We assume
that the marginal treatment effect ρ0 − ρ1 ≡ P(D = 1|T = 0) − P(D = 1|T = 1) is
positive, so that the default approach is to treat all subjects. The question is whether
a marker, Y , if measured prior to treatment provision, is useful for identifying a subset of subjects who can avoid treatment. Note that the scenario where the marginal
treatment effect is negative (or zero) and Y identifies a subset who benefit from
treatment can be handled by simply reversing the treatment labels.
We focus on the ideal setting for evaluating treatment efficacy, a randomized
and controlled trial (RCT) comparing T = 1 to T = 0. We assume to begin that Y
is continuous and measured at baseline on all trial participants. We generalize our
methods to case-control sampling from within an RCT in Section 6.2.
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3 Motivating Context
We illustrate our methods in the breast cancer treatment context. Women diagnosed
with estrogen-receptor-positive and node-positive breast cancer are typically treated
with both hormone therapy (e.g. tamoxifen) and adjuvant chemotherapy following
surgery. This is despite the fact that it is generally well-accepted in the clinical
community that only a subset of these women actually benefit from the adjuvant
chemotherapy, and the remaining women suffer its toxic side effects, not to mention the burden and cost of unnecessary treatment (Group (2005)). A high public
health priority is to identify biomarkers that can be used to predict which women
are and are not likely to benefit from the adjuvant chemotherapy (Dowsett, Goldhirsch, Hayes, Senn, Wood, and Viale (2007)). The Oncotype DX recurrence score
is an example of a biomarker that is currently being used in clinical practice for
this purpose. This marker is a proprietary combination of 21 genes whose expression levels are measured in the tumor tissue obtained at surgery (Paik, Shak, Tang,
Kim, Baker, Cronin, Baehner, Walker, Watson, and et al. (2004), Paik, Tang, Shak,
Chungyeul, Baker, Kim, Cronin, Baehner, Watson, Bryant, Constantino, Geyer,
Wickerham, and Wolmark (2006), Albain, Barlow, Shak, Hortobagyi, Livingston,
and Yeh (2010)). The marker has been shown to have value for identifying a subset of women who are unlikely to benefit from chemotherapy (Paik et al. (2006),
Albain et al. (2010)).
To illustrate our methods, we simulated a marker, Y1 , with the same performance as Oncotype DX, as seen in the SWOG SS8814 trial which evaluated
adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil) given
before tamoxifen for treating post-menopausal women with estrogen-receptor positive, node-positive breast cancer (Albain, Barlow, Davdin, Farrar, Burton, Ketchel,
and et al. (2009), Albain et al. (2010)). We also simulated another marker, Y2 ,
which we will demonstrate is a much stronger marker. The markers Y1 and Y2 are
measured at baseline for 1,000 participants randomized with equal probability to tamoxifen alone (T = 0) or tamoxifen plus chemotherapy (T = 1). The outcome, D, is
breast cancer recurrence or death within 5 years of randomization and the marginal
treatment effect is ρ0 − ρ1 = 0.24 − 0.21 = 0.03 as seen in SS8814. Marker Y1
is simulated to mimic the Oncotype DX distribution, being normally distributed
on the square-root scale with mean 4.8 and standard deviation 1.8, and marker Y2
is standard normal. Each marker is related to disease via a linear logistic model,
logitP(D = 1|T,Y ) = β0 + β1 T + β2Y + β3Y T , where for Y1 the model coefficients
are chosen to mimic the performance of the Oncotype DX recurrence score (Albain
et al. (2010)). Methods for simulating the data are described in the appendix.
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4 Methods for Evaluating Individual Markers
4.1 Treatment Rule
Given that the task is to decide between treatment and no treatment for each individual patient, it is common to define a binary rule for assigning treatment on the
basis of marker value. Let ∆(Y ) = P(D = 1|T = 0,Y ) − P(D = 1|T = 1,Y ) denote
the absolute treatment effect given marker value Y . The rule
do not treat if ∆(Y ) < 0
can be shown to be optimal in the sense that it minimizes the population disease rate
(Brinkley et al. (2010), Zhang et al. (2012), Janes, Pepe, and Huang (2012)). Some
of the marker performance measures we consider evaluate the properties of this
rule; other performance measures do not depend on a treatment rule. We refer to
subjects with ∆(Y ) < 0 as “marker-negatives” and ∆(Y ) > 0 as “marker-positives”.
More general treatment rules are considered in Section 6.1.

4.2 Descriptives
For descriptive analysis, it is useful to display the distribution of risk of disease as a
function of marker under each treatment. We plot “risk curves” P(D = 1|T = 1,Y )
and P(D = 1|T = 0,Y ) versus marker percentile F(Y ), where F is the cumulative
distribution function (CDF) of Y (Janes et al. (2011)). Figure 1 shows the risk
curves for the Oncotype-DX-like marker, Y1 , and the much better marker, Y2 . One
can visually assess the variability in response on each treatment as a function of
marker value and read off the plot the percent of patients with negative treatment
effects who can avoid chemotherapy, 46% for Y1 vs. 38% for Y2 .
Another informative display is the distribution of treatment effect, as summarized by ∆(Y ) vs. F∆ (∆(Y )) where F∆ is the CDF of ∆(Y ) (Huang et al. (2012)).
The example shown in Figure 2 reveals that Y2 has much greater variation in markerspecific treatment effect than does Y1 . For Y2 a greater proportion of marker-specific
treatment effects are extreme whereas for Y1 the range is smaller and most treatment
effects are near the average of ρ0 − ρ1 = 0.03.
These descriptives are simple extensions of predictiveness curves (Huang,
Sullivan Pepe, and Feng (2007), Pepe, Feng, Huang, Longton, Prentice, Thompson,
and Zheng (2008a)), which are used to evaluate the performance of markers for risk
prediction.
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4.3 Summary Measures
The following are useful measures for summarizing marker performance that depend on specification of the treatment rule:
• Decrease in population disease rate under marker-based treatment,
Θ = P(D = 1|T = 1) − [P(D = 1|T = 1, ∆(Y ) > 0)P(∆(Y ) > 0)
+ P(D = 1|T = 0, ∆(Y ) < 0)P(∆(Y ) < 0)]
= [P(D = 1|T = 1, ∆(Y ) < 0) − P(D = 1|T = 0, ∆(Y ) < 0)] P(∆(Y ) < 0)
• Average benefit of no treatment among marker-negatives,
Bneg = P(D = 1|T = 1, ∆(Y ) < 0) − P(D = 1|T = 0, ∆(Y ) < 0)
• Average benefit of treatment among marker-positives,
B pos = P(D = 1|T = 0, ∆(Y ) > 0) − P(D = 1|T = 1, ∆(Y ) > 0)
• Proportion marker-negative, Pneg = P(∆(Y ) < 0)
where we define P(D = 1|T, ∆(Y ) < 0) = 0 if P(∆(Y ) < 0) = 0. The measure Θ,
or a variation on it, has been advocated by many as a global measure of marker
performance (Song and Pepe (2004), Brinkley et al. (2010), Janes et al. (2011),
Gunter et al. (2007), Zhang et al. (2012), McKeague and Qian (2011)). Θ varies
between 0 and ρ1 . The minimum value 0 corresponds to an entirely useless marker
with constant marker-specific treatment effect, ∆(Y ) = ρ0 − ρ1 > 0 for all Y . For
such a marker, Θ = ρ1 − [ρ1 · 1 + 0 · 0] = 0. The maximum value of Θ is achieved
when P(D = 1|T = 1, ∆(Y ) > 0) = P(D = 1|T = 0, ∆(Y ) < 0) = 0, so that Θ =
ρ1 − [0 · P(∆(Y ) > 0) + 0 · P(∆(Y) < 0)] = ρ1 .
The constituents of Θ, namely Bneg and Pneg , are helpful for dissecting the
impact of the marker. The measures Bneg and B pos describe the average benefit
of the treatment policies recommended to marker-negatives and marker-positives,
respectively.
We also consider two marker performance measures that do not depend on
a treatment rule. Each represents a simple extension of a measure used to evaluate
markers for risk prediction (Pepe, Feng, and W. (2008b), Pencina, D’Agostino,
D’Agostino, and Vasan (2008), Gu and Pepe (2009)):
R

• Variance in treatment effect, V∆ = Var(∆(Y )) = (∆(Y ) − (ρ0 − ρ1 ))2 dF∆
• Total gain, the area Rbetween the treatment effect curve and the marginal treatment effect, T G = |∆(Y ) − (ρ0 − ρ1 )| dF∆
The V∆ and T G measures suffer because of lack of clinical interpretation, but have
the advantage of being independent of treatment rule and potentially form the basis
for more efficient comparisons of markers.
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Table 1 contains estimates of these performance measures for markers Y1
and Y2 in the breast cancer example. Focusing on Y2 , we see that the population
impact of Y2 -based-treatment is a 10% reduction in the disease rate; this is a consequence of 38% of patients avoiding adjuvant chemotherapy and a 26% reduction
in the event rate due to avoiding chemotherapy in this subgroup. Among markerpositives, chemotherapy decreases the disease rate by 21% on average. Less interpretable, but somewhat useful for global marker comparisons, are the values of
V∆ = 0.08 and T G = 0.22.

4.4 Estimation and Inference
Our proposed estimation and inference methods build on methodology developed
for risk prediction (see Huang et al. (2007), Huang and Pepe (2010b,a)). This section overviews these approaches which are evaluated in a small-scale simulation
study described in the appendix.
4.4.1 Estimation
Given data consisting of i.i.d copies of (Yi , Ti , Di ), i = 1, ..., N, the first step in estimation is to fit a model for disease risk as a function of T and Y . We use a general
linear regression risk model with an interaction between T and Y ,
g(P(D = 1|T,Y )) = β0 + β1 T + β2Y + β3Y T.

(1)

Typically we let g be the logit function because of its advantages with case-control
data (see Section 6.2) and because we have found logistic regression to be remarkably robust to model mis-specification. We note that the general linear model (1)
is flexible in that the marker Y can itself be a transformed marker value. The risk
and treatment effect estimates that result from fitting from this model are written
d 1 (Y ) =
d 0 (Y ) = g−1 (βb0 + βb2Y ), P(D
b = 1|T = 1,Y ) = Risk
b = 1|T = 0,Y ) = Risk
P(D
b ) = Risk
d 0 (Y ) − Risk
d 1 (Y ). We estimate the
g−1 (βb0 + βb1 + βb2Y + βb3Y ), and ∆(Y
marker and treatment effect distributions empirically and denote these by Fb and
d 0 (Y ) and Risk
d 1 (Y ) versus F(Y
b ). Pointwise α Fb∆ . The estimated risk curves are Risk
level horizontal confidence intervals inform about the variability in the proportion of
participants at or below a given risk level; we obtain these using the percentile bootb ) vs. Fb∆ . Here pointwise
strap method. The estimated treatment effect curve is ∆(Y
horizontal confidence intervals capture the variability in the estimated proportion of
individuals with treatment effects below a certain value.
For the summary measures that depend on the treatment rule, we consider
both “empirical” and “model-based” estimators. An empirical estimator uses the
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risk model (1) to classify individuals as marker-positive or marker-negative, and
the performance of this rule is estimated empirically. For a model-based estimator,
the risk model is used both to classify each individual and to estimate the performance of the classification rule. The estimators are listed below, where e and m
superscripts indicate empirical and model-based estimators and Pb denotes an empirical probability estimate:
b ) < 0)
b ∆(Y
Pbneg = P(
b ) < 0) − P(D
b ) < 0)
b = 1|T = 1, ∆(Y
b = 1|T = 0, ∆(Y
Bbeneg = P(D
Bbm
neg =

Z

b )I[∆(Y
b ) < 0] d Fb∆
−∆(Y

b ) > 0) − P(D
b ) > 0)
b = 1|T = 0, ∆(Y
b = 1|T = 1, ∆(Y
Bbepos = P(D
Bbmpos =

Z

b )I[∆(Y
b ) > 0] d Fb∆
∆(Y

b e = Bbe ∗ Pbneg
Θ
neg
m
b
b
b
Θ = Bm
neg ∗ Pneg

The treatment-rule-independent summary measures are estimated by the following
model-based estimators:
b∆ =
V

Z

Tc
G=

Z

b ) − (ρb0 − ρb1 ))2 d Fb∆
(∆(Y

b ) − (ρb0 − ρb1 )| d Fb∆ ,
|∆(Y

where ρb0 and ρb1 are empirical estimates of P(D = 1|T = 0) and P(D = 1|T = 1).
Confidence intervals for each summary measure can be obtained using the percentile bootstrap.
4.4.2 Hypothesis Testing
Testing whether a marker has any performance for treatment selection is of interest
for two reasons. First, this is a logical first step in marker evaluation. Second, the
performance measures described above have poor statistical properties at and near
the null of no marker performance. This is similar to problems that have been identified with measures of risk prediction model performance (see Vickers, Cronin,
and Begg (2011), Kerr, McClelland, Brown, and Lumley (2011), Pepe, Kerr, Longton, and Wang (2011), Seshan, Gonen, and Begg (2012), Demler, Pencina, and
D’Agostino (2012), Kerr, Wang, Janes, McClelland, Psaty, and Pepe (2012)); Section 7 includes further discussion of this point. Therefore, we advocate a simple
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pre-testing approach, whereby the marker performance measures are only estimated
if the null hypothesis H0 : Θ = 0 corresponding to null marker performance is rejected.
For an unbounded marker, under risk model (1), H0 is equivalent to H01 :
β3 = 0 where β3 is the coefficient of interaction in the risk model. Therefore H0
can be tested using a (most-powerful) likelihood ratio (LR) test for β3 . However if
Y is bounded, H01 implies H0 but the reverse does not hold; it is possible that β3 6= 0
but Θ = 0. Therefore we perform two hypothesis tests, splitting the type-I error
equally. We test H01 : β3 = 0 using a LR test and H02 : −β1 /β3 ∈
/ (Ymin ,Ymax ) using
a Wald or percentile-bootstrap-based test, where −β1 /β3 is the marker value where
∆(Y ) = 0 under model (1) and Ymin and Ymax are the known upper and lower limits
for Y . Note that there are other methods that could be employed for testing the null
of no marker performance (e.g. Gail and Simon (1985), Shuster and J. (1983));
optimizing this test is not our focus.
For the unbounded markers Y1 and Y2 in our breast cancer example, H0 is
rejected with p = 0.005 and p < 0.0001, respectively.

4.5 Calibration Assessment
Assessing model calibration is a basic step in marker evaluation. We rely on standard methods for visualizing and testing goodness of fit for the risk model (1).
Since patients are provided risk estimates under both treatment options, we assess
the fit of the model separately in the two treatment groups. Specifically, we define
a well-calibrated model to be one for which P(D = 1|T = 0, Risk0 (Y ) = r) ≈ r and
P(D = 1|T = 1, Risk1 (Y ) = r) ≈ r (Pepe and Janes (2012)). To assess this, we split
each treatment group t = 0, 1 into G equally-sized groups where the observations
d t (Y ). Commonly G = 10 and the groups are based
in each group have similar Risk
d t (Y ). In each group, we calculate the average predicted risks,
on quantiles of Risk
b = 1|T = t, G = g). Following Huang and
Risktg (Y ), and the observed risks, P(D
d 0 (Y ) and Risk
d 1 (Y ), overlaying the G
Pepe (2010a), we plot the distribution of Risk
observed risk values on the plot, as shown in Figure 3.
To formally assess model calibration, a traditional Hosmer-Lemeshow goodness of fit test (Lemeshow and Hosmer (1982)) can be applied separately to the two
treatment groups. Specifically, for group T = t the test statistic
b = 1|T = t, G = g) − Risktg (Y ))2
Ntg (P(D
HLt = ∑
,
Risktg (Y )(1 − Risktg (Y ))
g=1
G

where Ntg is the number of participants in the gth group for T = t, is compared to a
χ 2 distribution with G − 2 degrees of freedom.
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Another aspect of calibration is the extent to which the treatment effect
model fits well. We want to ensure that P(D = 1|T = 0, ∆(Y ) = δ ) − P(D = 1|T =
1, ∆(Y ) = δ ) ≈ δ . Following the approach above, we split the data into G evenlyb ) and calculate the average predicted treatment effect,
sized groups based on ∆(Y
b = 1|T = 0, G = g) − P(D
b = 1|T = 1, G =
∆g (Y ), and observed treatment effect, P(D
g), in each group. We plot the treatment effect curve and overlay the G observed
treatment effect values as shown in Figure 3. Based on Figure 3 we see that the
risk and treatment effect models for Y1 and Y2 in the breast cancer example are
well-calibrated; the Hosmer-Lemeshow test statistics are 4.5 (p = 0.81) and 8.9
(p = 0.35) given T = 0 and 5.0 (p = 0.76) and 2.9 (p = 0.94) given T = 1. The
Risk0 (Y2 ) and ∆(Y1 ) curves suggest some evidence of poor calibration, which in our
setting is attributable to sampling variability in the observed risks that are calculated
using 50 observations each.

5 Comparing Markers
The descriptives and summary measures proposed herein form the basis for comparing candidate markers. We assume that the two markers, Y1 and Y2 , are measured
on the same participants, i.e. that the data are paired. With unpaired data, the analyses described above can be applied to each individual data set and the estimated
summary measures are statistically independent.
For drawing inference about the relative performance of two markers, confidence intervals for the differences in performance measures and hypothesis tests of
whether these difference are different from zero are informative. These can both be
obtained by bootstrapping the differences in test statistics. While global measures
of marker performance such as Θ, V∆ , and T G are appropriate as the basis for formal marker comparisons, differences in the other summary measures inform about
the nature of the difference between markers.
The results of the comparative analysis for the breast cancer example are
shown in Table 1. We can see clearly that Y2 has uniformly better performance than
Y1 , with an associated 10% vs. 1% reduction in the disease rate. Despite the fact
that there are fewer marker-negative subjects based on Y2 , there is a much greater
benefit of no chemotherapy among Y2 -marker-negatives. In general the variation in
treatment effect is larger for Y2 .
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6 Extensions
6.1 General Treatment Rules
In some settings there may be additional consequences of treatment that are not
captured in the outcome, for example treatment-associated toxicities. This means
that a treatment effect somewhat above zero may still warrant no treatment because
it is offset by the other consequences of treatment. In these settings the optimal
treatment rule can be shown to be
do not treat if ∆(Y ) < δ ,
where δ > 0 is equal to the burden of treatment relative to that of disease (Vickers et al. (2007), Janes et al. (2012)). The performance methods described above
generalize naturally to this treatment rule, where
Θ(δ ) = P(D = 1|T = 1) − [P(D = 1|T = 1, ∆(Y ) > δ )P(∆(Y ) > δ )
+P(D = 1|T = 0, ∆(Y ) < δ )P(∆(Y ) < δ )]
Bneg (δ ) = P(D = 1|T = 1, ∆(Y ) < δ ) − P(D = 1|T = 0, ∆(Y ) < δ )
Pneg (δ ) = P(∆(Y ) < δ )
B pos (δ ) = P(D = 1|T = 0, ∆(Y ) > δ ) − P(D = 1|T = 1, ∆(Y ) > δ ),
and the V∆ and T G measures are independent of treatment rule.

6.2 Case-Control Sampling
The methods described above apply to the setting where the marker is measured
at baseline on all RCT participants. However when the outcome D is rare, casecontrol sampling from within the RCT is a well-known efficient alternative that
recovers much of the information contained in the entire trial population. This
section extends the methods to the setting where the data consist of a case-control
sample from the RCT, or a case-control sample stratified on treatment assignment,
T . We consider case-control designs that sample all or a fixed proportion of the
cases in the RCT, as well as a number of controls (perhaps stratified on T ) that is a
fixed multiple of the number of cases sampled.
Consider first unstratified case-control sampling. Suppose ND and ND̄ cases
and controls occur in the trial “cohort” (N = ND + ND̄ ). The case-control sample
consists of a sample of nD = f · ND cases and nD̄ = k · nD controls, where f ∈ (0, 1]
and the control:case ratio k is an integer. Commonly all the cases are sampled
( f = 1) and 1-5 controls are sampled per case. Alternatively f may be set to a value
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less than 1 for a common disease or when budget concerns or sample availability
limit the number of cases that can be sampled; in these instances we assume that
selection into the case-control sample is completely random conditional on D = 1.
Let S = 1 be an indicator of selection into the case-control sample. Given
the case-control data, the task is to correct the estimates of P(D = 1|T,Y, S = 1)
and P(∆(Y ) < δ |S = 1) for the case-control sampling. Suppose that an estimate of
P(D = 1) is available from the cohort. The following identity is used to correct the
estimates of P(D = 1|T,Y, S = 1) for the case-control sampling:
logitP(D = 1|T,Y ) = logitP(D = 1|T,Y, S = 1)
+ logitP(D = 1) − logitP(D = 1|S = 1).
This identity follows from Bayes’ Theorem and was originally cited by Prentice and
Pyke (1979) as the rationale for using logistic regression to model risk with casecontrol data. Note that the first term on the right hand side can be estimated using
the logistic regression risk model (1) fit to the case-control data, and an estimate of
the second term is available from the trial cohort. The third term is estimated from
the case-control data.
The distribution of ∆(Y ), or equivalently of Y itself, can be estimated in the
cases and controls in the case-control data and corrected to the cohort distribution
via
b = 0) + Fb∆cc (Y )P(D
b = 1),
Fb∆ (Y ) = Fb∆ccD̄ (Y )P(D
D

where superscript cc denotes estimation in the case-control sample and D and D̄
subscripts denote case and control subsets.
We use a modified bootstrapping procedure for case-control data. To reproduce the variability in the cohort from which the case-control study is sampled,
b = 1)) and set N ∗ = N − N ∗ . Next we sample
we first sample ND∗ ∼ Bin(N, P(D
D
D̄
∗
∗
∗
nD = f · ND cases and nD̄ = k · n∗D controls from the subjects in the case-control
study. The estimation procedure is then performed in each bootstrap sample and
quantiles of the bootstrap distribution are used to characterize uncertainty.
Case-control sampling stratified on treatment assignment can also be accommodated. Here we assume a cohort with (ND0 , ND̄0 , ND1 , ND̄1 ) subjects in each
D×T stratum. The case-control sample consists of nD0 = f0 ·ND0 and nD1 = f1 ·ND1
cases for fixed proportions f0 and f1 in the two treatment groups, and nD̄0 = k0 · nD0
and nD̄1 = k1 · nD1 controls for fixed control:case ratios k0 and k1 . Assume that estimates of P(D = 1|T = 0), P(D = 1|T = 1), and P(T = 1) are available from the
cohort. A similar identity can be exploited for estimation:
logitP(D = 1|T,Y ) = logitP(D = 1|T,Y, S = 1) + logitP(D = 1|T )
− logitP(D = 1|T, S = 1)
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The first component on the right hand side is estimable using the risk model (1) fit to
the stratified case-control data, the second component is available from the cohort,
and the third component is estimated from the case-control data. The distribution
of ∆(Y ) combines empirical CDFs from the four D × T strata:
b = 0, T = 1)
b = 0, T = 0) + Fb∆cc (Y )P(D
Fb∆ (Y ) = Fb∆ccD̄0 (Y )P(D
D̄1

b = 1, T = 0) + Fb∆cc (Y )P(D
b = 1, T = 1).
+ Fb∆ccD0 (Y )P(D
D1

∗ ∼ Bin(N , P(D
Bootstrapping is implemented by first sampling ND0
= 1|T = 0))
0 b
∗
b = 1|T = 1)) where Nt = NDt + ND̄t . After setting N ∗ =
and ND1 ∼ Bin(N1, P(D
D̄0
∗ and N ∗ = N − N ∗ , the stratified case-control sample is then sampled
N0 − ND0
1
D1
D̄1
from the case-control subjects.
For calibration assessment, we implement a variation on the Hosmer-Lemeshow
test applied to case-control data, using methods described by Huang and Pepe
(2010a).

7 Discussion
This paper proposes a unified statistical framework for evaluating a candidate treatment selection marker and for comparing two markers. Estimation and inference
techniques are described for the setting where the marker or markers are measured
on all or a treatment-stratified case-control sample of participants in a randomized,
controlled trial. An R software package was developed which implements these
methods. Developing a solid framework for evaluating and comparing markers is
fundamental for accomplishing more sophisticated tasks such as combining markers, accounting for covariates, and assessing the improvement in performance associated with adding a new marker to a set of established markers.
Our approach to marker evaluation also applies when the marker is discrete.
In addition, it can be applied when there are multiple markers and interest lies in
evaluating their combination; ∆(Y ) = P(D = 1|T = 0,Y ) −P(D = 1|T = 1,Y ) is the
combination of interest and the measures described here can be used to summarize
the performance of this combination.
This work builds on existing approaches for evaluating markers for risk prediction (see Pepe and Janes (2012), Huang et al. (2007), Gu and Pepe (2009)). It
also relates to existing methodology for evaluating treatment selection markers in
that our preferred marker performance measure has been advocated in several recent
papers (Song and Pepe (2004), Brinkley et al. (2010), Janes et al. (2011), Gunter
et al. (2007), Zhang et al. (2012), McKeague and Qian (2011)).
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There are some challenges with making inference about the performance
measures we propose, similar to problems that have been identified with measures of risk prediction model performance including the area under the ROC curve
(Vickers et al. (2011), Pepe et al. (2011), Seshan et al. (2012), Demler et al. (2012)),
the integrated discrimination index (Kerr et al. (2011)), and the net reclassification
index (Kerr et al. (2012)). The problems arise when the sample size is modest and
marker performance is weak. In particular for the Oncotype DX example, given
that the marker is weak and the primary study evaluating its performance by Albain
et al. (2010) included just 367 women, our simulation results suggest that the resultant estimate of Θ is likely an over-estimate and that the confidence interval may be
conservative. For this reason, we propose testing for non-null marker performance
prior to estimating the magnitude of performance. This approach performed reasonably well in our simulation studies, but improved approaches to inference, for
the treatment selection as well as risk prediction problem, merit investigation.
The methods described here can and should be extended to accommodate
time-to-event outcomes. The conceptual framework applies, with the task being to
predict risk of the outcome by a specified landmark time. The methods may also
be generalized to an observational study setting, or to a setting where data on the
two treatments come from two different studies– perhaps historical data are paired
with a single-arm trial of T = 1. However the usual concerns about measured and
unmeasured confounding in estimating the treatment effect apply. In this setting an
analyst would be well-advised to stratify on variables that are potentially associated
with treatment provision and outcome.

8 Appendix
8.1 Simulation Studies
This section describes a small-scale simulation study that was performed to evaluate
the statistical performance of our methods. Data were simulated to reflect the breast
cancer RCT example, with T an indicator of chemotherapy in addition to tamoxifen, randomly assigned to half of study participants. Rates of 5-year breast cancer
recurrence or death (D) were set to 21% and 24% with and without chemotherapy,
respectively, as in SWOG SS8814 (Albain et al. (2010)). We explored the performance of the methods for a weak marker and a strong marker, both of which relate to
D via the linear logistic model (1). The weak marker, Y1 , mimics the performance of
the Oncotype-DX recurrence score as seen in (Albain et al. (2010)); Y1 is normally
distributed on the square-root scale with mean 4.8 and standard deviation 1.8. The
strong marker, Y2 , follows a standard normal distribution. To simulate data, we first
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generated potential outcomes D(1) and D(0) with and without treatment, respectively; marker values were generated from a distribution P(D(0), D(1)|Y j ), j = 1, 2
that yields marginal linear-logistic models (1); and treatment assignment, T , was
generated independent of potential outcomes and marker values. True values for the
marker performance measures were calculated as the average parameter estimates,
using the true risk function (1), across 10 very large datasets (N = 20, 000, 000).
We explore the bias of the parameter estimates and false-coverage probabilities of the bootstrap percentile confidence intervals (CIs) for sample sizes ranging
from N = 250 to N = 5, 000. A total of 5,000 simulations were performed for each
sample size. To explore the impact of our proposed pre-testing strategy, whereby the
parameters are not estimated if H0 : Θ = 0 is not rejected, we evaluate the parameter
estimates and confidence intervals marginally and conditionally. Marginal means
of parameter estimates include all estimates regardless of H0 rejection, and conditional means are computed only among datasets where H0 is rejected. The following probabilities of false coverage of nominal 95% CIs are evaluated: 1. Marginal
probability of false coverage, where CIs are calculated regardless of H0 rejection;
2. Conditional probability of false coverage, computed only among datasets where
H0 is rejected; and 3. Probability of rejecting H0 and the CI not covering the true
value, termed the “false conclusion probability” (Benjamini and Yekuteili (2005)).
8.1.1 Strong Marker
The results for the strong marker are contained in Tables A.1 and A.2. For this
marker, we see that the estimates and CIs have uniformly good performance. Marginal
bias is small and false coverage is near nominal; the pre-testing has no impact because of the 100% power to reject H0 for this marker.
8.1.2 Weak Marker
The results for the weak marker are contained in Tables A.3 and A.4. With n =
250 or 500, conditional on rejecting H0 the bias in parameter estimates and falsecoverage of CIs can be substantial; however rejecting H0 is unlikely with power
21% or 36%. Marginally, mean parameter estimates are substantially closer to their
true values and false-coverage probabilities are generally near-nominal. False conclusion probabilities are less than nominal but sometimes substantially below 0.05
indicating over-conservatism. With n = 1, 000 (5,000), conditional and marginal
bias is generally small and false-coverage probabilities are near or below nominal. False conclusion probabilities continue to be less than nominal. This example
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demonstrates that, for markers with near-null performance, substantial sample sizes
are required for accurate inference.

8.2 Software
We developed a package in the open-source software R called TreatmentSelection
that implements our methods for evaluating individual markers and for comparing
markers. The software is available at http://labs.fhcrc.org/janes/index.html. The
following functions are included:
• TrtSel creates a treatment selection object
• evalTrtSel evaluates a treatment selection object, producing estimates and
confidence intervals for the summary measures described in Section 4.3
• plotTrtSel plots a treatment selection object, producing risk curves and the
treatment effect curve described in Section 4.2
• calibrateTrtSel assesses the calibration of a fitted risk model and treatment effect model using methods described in Section 4.5
• compareTrtSel compares two markers using methods described in Section
5
Case-control and treatment-stratified case-control sampling are accommodated.
Here we illustrate use of the code by showing how the results shown in
Figures 1-3 and Table 1 of the main text are produced. First we load the data using
the following commands.
simData <- read.csv("ExampleData.csv",header=T)
> simData[1:10,]
T D
Y1
Y2
1 1 1 39.9120 -0.8535
2 1 0 6.6820 0.2905
3 1 0 6.5820 0.0800
4 0 0 1.3581 1.1925
5 0 0 7.6820 -0.2070
6 0 0 41.1720 -0.0880
7 1 0 19.4920 0.1670
8 1 1 20.8220 -1.0485
9 0 0 6.9620 -0.2435
10 0 0 2.5020 0.2030
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D <- simData$D
T <- simData$T
Y1 <- simData$Y1
Y2 <- simData$Y2
Treatment selection objects are created and displayed for Y1 and Y2 using the commands
trtsel.Y1 <- TrtSel(disease = D, treatment = T, marker = Y1,
study.design="randomized cohort")
> trtsel.Y1
Model Fit:
Link function: logit
Coefficients:
Estimate
(Intercept) -2.51814383
trt
0.48938620
marker
0.04760056
trt:marker -0.02318881

Std. Error
z value
Pr(>|z|)
0.235642511 -10.686288 1.179991e-26
0.311762857
1.569739 1.164759e-01
0.006453791
7.375597 1.636104e-13
0.008324063 -2.785756 5.340300e-03

Derived Data: (first ten rows)
disease trt marker fittedrisk.t0 fittedrisk.t1
trt.effect marker.neg
1
1
1 39.9120
0.35016583
0.2583742 0.0917916549
0
2
0
1 6.6820
0.09974358
0.1340472 -0.0343036269
1
3
0
1 6.5820
0.09931697
0.1337641 -0.0344471266
1
4
0
0 1.3581
0.07918316
0.1196652 -0.0404820847
1
5
0
0 7.6820
0.10410005
0.1369063 -0.0328062456
1
6
0
0 41.1720
0.36393311
0.2643117 0.0996213622
0
7
0
1 19.4920
0.16933976
0.1746644 -0.0053246137
1
8
1
1 20.8220
0.17843231
0.1793943 -0.0009620341
1
9
0
0 6.9620
0.10094678
0.1348426 -0.0338958439
1
10
0
0 2.5020
0.08324538
0.1226384 -0.0393929781
1

trtsel.Y2 <- TrtSel(disease = D, treatment = T, marker = Y2,
study.design="randomized cohort")
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> trtsel.Y2
Model Fit:
Link function: logit
Coefficients:
Estimate Std. Error
z value
Pr(>|z|)
(Intercept) -1.2107912 0.1131642 -10.699416 1.024216e-26
trt
-0.5169008 0.1863643 -2.773604 5.543912e-03
marker
0.5779172 0.1148643
5.031305 4.871514e-07
trt:marker -2.0455033 0.2064547 -9.907756 3.851994e-23

Derived Data: (first ten rows)

1
2
3
4
5
6
7
8
9
10

disease trt marker fittedrisk.t0 fittedrisk.t1
trt.effect marker.neg
1
1 -0.8535
0.1539379
0.38340813 -0.229470242
1
0
1 0.2905
0.2605896
0.10395563 0.156633982
0
0
1 0.0800
0.2378401
0.13644937 0.101390712
0
0
0 1.1925
0.3724723
0.02995087 0.342521474
0
0
0 -0.2070
0.2090899
0.19405065 0.015039232
0
0
0 -0.0880
0.2206903
0.16818515 0.052505186
0
0
1 0.1670
0.2470740
0.12209072 0.124983277
0
1
1 -1.0485
0.1398258
0.45290799 -0.313082172
1
0
0 -0.2435
0.2056229
0.20256576 0.003057187
0
0
0 0.2030
0.2509647
0.11653995 0.134424710
0

The descriptives shown in Figure 1 are produced using
plot(trtsel.Y1, main = "Y1: Oncotype-DX-like marker", bootstraps = 500,
trt.names=c("chemo.","no chemo."))
plot(trtsel.Y2, main = "Y2: Strong marker", bootstraps = 500,
trt.names=c("chemo.","no chemo."))
Calibration is assessed and displayed as shown in Figure 3 using
cali.Y1 <- calibrate(trtsel.Y1)
> cali.Y1
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Hosmer - Lemeshow test for model calibration
---------------------------------------------No Treatment (trt = 0):
Test Statistic = 4.496,

DF = 8,

p value = 0.8098813

Treated (trt = 1):
Test Statistic = 4.986,

DF = 8,

p value = 0.7591213

cali.Y2 <- calibrate(trtsel.Y2)
> cali.Y2
Hosmer - Lemeshow test for model calibration
---------------------------------------------No Treatment (trt = 0):
Test Statistic = 8.896,

DF = 8,

p value = 0.3511235

Treated (trt = 1):
Test Statistic = 2.868,

DF = 8,

p value = 0.9423597

calibrate(trtsel.Y1, plot.type = "risk.t0")
calibrate(trtsel.Y2, plot.type = "risk.t0")
calibrate(trtsel.Y1, plot.type = "risk.t1")
calibrate(trtsel.Y2, plot.type = "risk.t1")
calibrate(trtsel.Y1, plot.type = "treatment effect")
calibrate(trtsel.Y2, plot.type = "treatment effect")
The summary measure estimates and confidence intervals shown in Table 1 are
obtained by
eval.Y1 <- evalTrtSel(trtsel.Y1, bootstraps = 500)
eval.Y1
> eval.Y1

Hypothesis test:
------------------
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No marker by treatment interaction:

P value = 0.0053403
Z value = -2.785756

Summary Measure Estimates (with 95% confidence intervals)
----------------------------------------------------------Decrease in disease rate under marker-based treatment (Theta)
Empirical:
0.013 (-0.009,0.05)
Model Based: 0.01 (0,0.042)
Proportion marker negative:
0.461 (0,0.709)
Average benefit of no treatment among marker-negatives (B.neg)
Empirical:
0.029 (-0.066,0.085)
Model Based: 0.023 (0,0.064)
Average benefit of treatment among marker-positives (B.pos)
Empirical:
0.089 (0.017,0.162)
Model Based: 0.098 (0.039,0.16)

Variance in estimated treatment effect :
0.007 (0.001,0.02)
Total Gain:
0.066 (0.023,0.11)

eval.Y2 <- evalTrtSel(trtsel.Y2, bootstraps = 500)
eval.Y2
> eval.Y2

Hypothesis test:
-----------------No marker by treatment interaction:

P value = 3.851994e-23
Z value = -9.907756

Summary Measure Estimates (with 95% confidence intervals)
----------------------------------------------------------Decrease in disease rate under marker-based treatment (Theta)
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Empirical:
Model Based:

0.09 (0.063,0.124)
0.099 (0.072,0.128)

Proportion marker negative:
0.377 (0.306,0.474)
Average benefit of no treatment among marker-negatives (B.neg)
Empirical:
0.238 (0.175,0.305)
Model Based: 0.262 (0.213,0.31)
Average benefit of treatment among marker-positives (B.pos)
Empirical:
0.203 (0.153,0.256)
Model Based: 0.211 (0.171,0.251)

Variance in estimated treatment effect :
0.08 (0.058,0.108)
Total Gain:
0.224 (0.188,0.265)
The markers are compared based on summary measures using
mycompare <- compare(trtsel1 = trtsel.Y1, trtsel2 = trtsel.Y2,
bootstraps = 500)
> mycompare
Summary Measure Estimates
(with 95% confidence intervals)
marker 1
|
marker 2
|
difference
(p-value)
-----------------------------------------------------------------------Decrease in disease rate under marker-based
Empirical:
0.013
|
0.090
(-0.010,0.044) | (0.060,0.122)
Model Based:
0.010
|
0.099
(0.000,0.037) | (0.071,0.129)

treatment (Theta)
|
-0.076
| (-0.111,-0.042)
|
-0.088
| (-0.115,-0.061)

Proportion marker negative:
0.461
|
0.377
(0.000,0.700) | (0.304,0.470)

|
0.084
| (-0.358,0.236)

(< 0.002)
(< 0.002)

(0.768)
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Average benefit of no treatment among marker-negatives (B.neg)
Empirical:
0.029
|
0.238
|
-0.209
(-0.106,0.082) | (0.170,0.309) | (-0.342,-0.129)
Model Based:
0.023
|
0.262
|
-0.239
(0.000,0.057) | (0.209,0.310) | (-0.294,-0.178)
Average benefit of treatment among marker-positives (B.pos)
Empirical:
0.089
|
0.203
|
-0.114
(0.020,0.157) | (0.157,0.263) | (-0.193,-0.043)
Model Based:
0.098
|
0.211
|
-0.113
(0.035,0.162) | (0.176,0.258) | (-0.184,-0.052)

Variance in estimated treatment effect :
0.007
|
0.080
(0.001,0.019) | (0.057,0.109)

(< 0.002)
(< 0.002)

(< 0.002)
(< 0.002)

|
-0.073
| (-0.103,-0.046)

(< 0.002)

|
-0.158
| (-0.221,-0.102)

(< 0.002)

Total Gain:
0.066
(0.024,0.110)

|
0.224
| (0.187,0.263)

and visually (as in Figure 2) using
plot(mycompare, bootstraps = 500, main="",marker.names=c("Y1","Y2"))
If instead the dataset with D, Y1 , and T measurements consisted of a casecontrol sample from within an RCT, given estimates of P(D = 1) and P(T = 1)
from the trial cohort (call these Risk.cohort and Rand. f rac) and the size of the trial
cohort, N, the only modification would be in creating the treatment selection object:
cctrtsel.Y1 <- TrtSel(disease = D, treatment = T, marker = Y1,
cohort.attributes = c(N, Risk.cohort, Rand.frac),
study.design="nested case control")
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Figure 1: Risk of disease as a function of treatment assignment and marker percentile, for Y1 , the Oncotype-DX-like marker (top), and the strong marker, Y2 (bottom). Horizontal pointwise 95% confidence intervals are shown. Fourty-six percent
of women have negative treatment effects according to Y1 vs. 38% with Y2 ; these
women can avoid adjuvant chemotherapy.

Hosted by The Berkeley Electronic Press

0.5
0.0

Average
Zero
Y1
Y2

−1.0

−0.5

treatment effect

Treatment Effect

0.0

0.2

0.4

0.6

0.8

1.0

% population below treatment effect

Figure 2: Distribution of the treatment effect, as measured by the difference in
disease rate without vs. with treatment, ∆(Y ) = P(D = 1|T = 0,Y ) − P(D = 1|T =
1,Y ), for the Oncotype-DX-like marker (Y1 ) and the strong marker (Y2 ). Horizontal
pointwise 95% confidence intervals are shown.
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Table 1: Estimates of various measures of marker performance for the Oncotype-DX-like marker (Y1 ) and the strong
marker (Y2 ) in the breast cancer example.
Marker Y1
Marker Y2
Marker Y1 vs. Y2
Measure Estimator
Estimate
Estimate
Estimated Diff.
P-value
(95% CI)
(95% CI)
(95% CI)
for diff.
be
Θ
Θ
0.013 (-0.010,0.044) 0.090 (0.060,0.122) -0.076 (-0.111,-0.042) < 0.002
m
b
Θ
0.010 (0.000,0.037) 0.099 (0.071,0.129) -0.088 (-0.115,-0.061) < 0.002
0.029 (-0.106,0.082) 0.238 (0.170,0.309) -0.209 (-0.342,-0.129) < 0.002
Bneg
Bbeneg
m
0.023 (0.000,0.057) 0.262 (0.209,0.310) -0.239 (-0.294,-0.178) < 0.002
Bbneg
e
0.089 (0.020,0.157) 0.203 (0.157,0.263) -0.114 (-0.193,-0.043) < 0.002
B pos
Bbpos
m
0.098 (0.035,0.162) 0.211 (0.176,0.258) -0.113 (-0.184,-0.052) < 0.002
Bbpos
Pneg
Pbneg
0.461 (0.000,0.700) 0.377 (0.304,0.470) 0.084 (-0.358,0.236)
0.768
b∆
0.007 (0.001,0.019) 0.080 (0.057,0.109) -0.073 (-0.103,-0.046) < 0.002
V
V∆
TG
Tc
G
0.066 (0.024,0.110) 0.224 (0.187,0.263) -0.158 (-0.221,-0.102) < 0.002
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Figure 3: Plots assessing calibration of the risk and treatment effect models, for the
Oncotype-DX-like marker (left) and the strong marker (right).
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Table A.1: Mean parameter estimates for the strong marker. For Θ, Bneg , and B pos , results are shown for both empirical
and model-based estimators. The probability of rejecting H0 : Θ = 0 is shown along with marginal and conditional means
of parameter estimates. Marginal means include all parameter estimates, regardless of H0 rejection. Conditional means
are only computed among trials for which H0 was rejected. True parameter values are shown in parentheses.
Prob.
Θ
Pneg
Bneg
B pos
V∆
TG
Reject
(0.110)
(0.379)
(0.291)
(0.228)
(0.094) (0.245)
H0
Mod. Emp.
Mod. Emp. Mod. Emp.
N
Marginal 250
1 0.113 0.112
0.380 0.295 0.293 0.230 0.229
0.097
0.246
500
1 0.112 0.112
0.380 0.293 0.293 0.230 0.230
0.096
0.246
1000
1 0.111 0.111
0.379 0.292 0.292 0.229 0.229
0.095
0.246
5000
1 0.110 0.110
0.379 0.291 0.291 0.228 0.228
0.094
0.246
Conditional 250
1 0.113 0.112
0.380 0.295 0.293 0.230 0.229
0.097
0.246
500
1 0.112 0.112
0.380 0.293 0.293 0.230 0.230
0.096
0.246
1000
1 0.111 0.111
0.379 0.292 0.292 0.229 0.229
0.095
0.246
5000
1 0.110 0.110
0.379 0.291 0.291 0.228 0.228
0.094
0.246
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Table A.2: False coverage results for the strong marker. For Θ, Bneg , and B pos , results are shown for both empirical and
model-based estimators. Percentile bootstrap confidence intervals (CIs) are evaluated using: Marginal false coverage, the
proportion of CIs that do not cover the true value regardless of H0 rejection; conditional false coverage, the proportion of
CIs that do not cover the true value among datasets where H0 is rejected; and false conclusion probability, the proportion
of datasets where H0 is rejected and the CI does not cover the true value. The probability of rejecting H0 : Θ = 0 is also
shown.
Prob.
Θ
Pneg
Bneg
B pos
V∆
TG
N Reject H0 Mod. Emp.
Mod. Emp. Mod. Emp.
250
1 0.059 0.045 0.052 0.056 0.030 0.051 0.034 0.056 0.056
Marg.
500
1 0.054 0.043 0.053 0.050 0.031 0.050 0.038 0.054 0.053
false
1000
1 0.056 0.055 0.051 0.049 0.044 0.047 0.044 0.055 0.055
cov.
5000
1 0.055 0.051 0.055 0.056 0.048 0.052 0.049 0.053 0.056
250
1 0.059 0.045 0.052 0.056 0.030 0.051 0.034 0.056 0.056
Cond.
500
1 0.054 0.043 0.053 0.050 0.031 0.050 0.038 0.054 0.053
false
1000
1 0.056 0.055 0.051 0.049 0.044 0.047 0.044 0.055 0.055
cov.
5000
1 0.055 0.051 0.055 0.056 0.048 0.052 0.049 0.053 0.056
250
1 0.059 0.045 0.052 0.056 0.030 0.051 0.034 0.056 0.056
500
1 0.054 0.043 0.053 0.050 0.031 0.050 0.038 0.054 0.053
False
1 0.056 0.055 0.051 0.049 0.044 0.047 0.044 0.055 0.055
concl. 1000
5000
1 0.055 0.051 0.055 0.056 0.048 0.052 0.049 0.053 0.056
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Table A.3: Mean parameter estimates for the weak marker. For Θ, Bneg , and B pos , results are shown for both empirical
and model-based estimators. The probability of rejecting H0 : Θ = 0 is shown along with marginal and conditional means
of parameter estimates. Marginal means include all parameter estimates, regardless of H0 rejection. Conditional means
are only computed among trials for which H0 was rejected. True parameter values are shown in parentheses.
Prob.
Θ
Pneg
Bneg
B pos
V∆
TG
Reject
(0.0095)
(0.439)
(0.022)
(0.073)
(0.005) (0.050)
H0
Mod. Emp.
Mod. Emp. Mod. Emp.
N
Marginal 250 0.217 0.022 0.022
0.423 0.036 0.036 0.090 0.090
0.009
0.060
500 0.364 0.016 0.015
0.410 0.027 0.026 0.080 0.080
0.007
0.055
1000
0.63 0.013 0.013
0.405 0.024 0.024 0.076 0.076
0.006
0.054
5000 0.999 0.010 0.010
0.426 0.022 0.022 0.073 0.073
0.005
0.053
Conditional 250 0.217 0.042 0.041
0.547 0.071 0.069 0.159 0.154
0.022
0.112
500 0.364 0.026 0.025
0.509 0.046 0.044 0.117 0.117
0.013
0.084
1000 0.630 0.017 0.017
0.473 0.032 0.032 0.091 0.090
0.008
0.066
5000 0.999 0.010 0.010
0.426 0.022 0.022 0.073 0.073
0.005
0.053
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Table A.4: False coverage results for the weak marker. For Θ, Bneg , and B pos , results are shown for both empirical and
model-based estimators. Percentile bootstrap confidence intervals (CIs) are evaluated using: Marginal false coverage, the
proportion of CIs that do not cover the true value regardless of H0 rejection; conditional false coverage, the proportion of
CIs that do not cover the true value among datasets where H0 is rejected; and false conclusion probability, the proportion
of datasets where H0 is rejected and the CI does not cover the true value. The probability of rejecting H0 : Θ = 0 is also
shown.
Prob.
Θ
Pneg
Bneg
B pos
V∆
TG
N Reject H0 Mod. Emp.
Mod. Emp. Mod. Emp.
250
0.217 0.054 0.030 0.059 0.053 0.023 0.063 0.026 0.034 0.035
Marg.
500
0.364 0.043 0.021 0.052 0.034 0.014 0.048 0.022 0.029 0.030
false
1000
0.630 0.050 0.026 0.055 0.034 0.015 0.047 0.018 0.052 0.051
cov.
5000
0.999 0.057 0.037 0.058 0.058 0.020 0.058 0.036 0.060 0.058
250
0.217 0.162 0.089 0.102 0.190 0.074 0.248 0.088 0.158 0.161
Cond.
500
0.364 0.083 0.043 0.065 0.086 0.032 0.121 0.057 0.081 0.083
false
1000
0.630 0.045 0.028 0.043 0.047 0.023 0.061 0.028 0.046 0.044
cov.
5000
0.999 0.056 0.037 0.058 0.057 0.020 0.057 0.035 0.058 0.057
0.217 0.035 0.019 0.022 0.041 0.016 0.054 0.019 0.034 0.035
250
Marg.
500
0.364 0.030 0.016 0.024 0.031 0.012 0.044 0.021 0.029 0.030
false
1000
0.630 0.028 0.018 0.027 0.030 0.014 0.038 0.018 0.029 0.028
concl.
5000
0.999 0.056 0.037 0.058 0.057 0.020 0.057 0.035 0.058 0.057
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